ClinicalTrials.gg
Not yet recruitingNCT07798024Updated Sep 1, 2026

Effect of IRPM-APD on Clinical Outcomes for PD Patients

An observational study in Peritoneal Dialysis (PD), sponsored by First Affiliated Hospital, Sun Yat-Sen University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by First Affiliated Hospital, Sun Yat-Sen University · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
600
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the impact of an integrated remote patient monitoring model on clinical, operational, and health-economic outcomes for patients receiving APD

02

Conditions studied

  • Peritoneal Dialysis (PD)

Keywords

  • Peritoneal Dialysis
  • automated peritoneal dialysis
  • remote patient monitoring
03

In context

Lead sponsor

First Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 162 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Incident APD patients of multiple centesr who meet the inclusion criteria will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Incident PD patients with age ≥18 years;
  • For APD-IRPM group, patients preferred to use the APD machine of Homechoice Claria®;
  • For Control group, patients treated with APD therapy (without RPM system) at the initiation of PD;
  • Signed an form.

Exclusion criteria

Exclusion Criteria:

  • Peritonitis occurred within 6 weeks before the baseline assessment.
  • Urinary catheter was removed or abdominal surgery was performed within 60 days before the baseline assessment.
  • Patients who have severe cognitive impairment or mental illness, rendering them unable to complete the follow-up.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
600 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Groups and cohorts

  • CON

    In the APD group, the PD team did not have access to the information transmitted by the RPM device; the management of patients in the APD group was carried out in the usual way.

  • IRPM-APD

    Doctors and nurses were instructed to review daily the data provided by the IRPM-APD device for IRPM-APD arms patients. In detail, daily data includes the day and time of connection, the duration of treatment per day, total exchange volume, the number of cycles, use or not of wet day (i.e. daytime exchange in the preceding day), dialysate volume infused, total dwell time, dwell time per exchange, actual time for filling and draining per exchange, drain volume per dwell and total treatment, cycle profile, total and dwell ultrafiltration, and number of events per treatment. The number and reason for alarms, events and bypass drain were also recorded and reviewed.

    Other: Integrated remote patient monitoring (IRPM)

Interventions

  • OtherIntegrated remote patient monitoring (IRPM)

    IRPM provided information gathered by RPM of treatment data day-by-day, and achieved higher-frequency information feedback and clinical decision support. Additionally, the current knowledge about the effects of RPM in APD limited real-world research.

06

What researchers measure

Primary outcomes

  1. Composite indices were constructed based on four SONG-PD (Standardized Outcomes in Nephrology-Peritoneal Dialysis) core outcomes: mortality, cardiovascular (CV) diseases, PD infection and technique survival, complemented by SONG-PD middle.

    Primary endpoints were time to the first event of Composite Index, including mortality (all-cause mortality and CV-related mortality), transferring to hemodialysis (technique failure), and peritonitis.

    Time frame: From date of randomization until the date of first event, whichever came first, assessed at least 24 months.

Secondary outcomes

  1. Adverse events

    Rate of adverse events in one year.

    Time frame: From date of randomization until the end of follow-up, assessed at least 24 months

  2. Hospitalizations linked to adverse events possibly related to potentially preventable causes such as fluid overload (edema, hypertension and heart failure)

    Rate of hospitalizations in one year.

    Time frame: From date of randomization until the end of follow-up, assessed at least 24 months

  3. Unplanned visits, defined as any unscheduled medical contacts (including outpatient visits, emergency room visits, or phone calls) made by peritoneal dialysis patients because of unexpected health issues, beyond the routine follow-up schedule.

    Rate of unplanned visits in one year.

    Time frame: From date of randomization until the end of follow-up, assessed at least 24 months.

  4. Nutritional condition (evaluated by SGA)

    Change of nutritional condition in one year.

    Time frame: From date of randomization until study completion, assessed at least 24 months.

  5. Quality of life (evaluated by SF36)

    The Short Form 36-item Health Survey (SF-36) scores range from 0 to 100, with higher scores indicating better health status and fewer limitations.

    Time frame: Change of quality of life in one year.

  6. Residual renal function decline

    Rate of residual renal function decline in one year.

    Time frame: From date of randomization until the end of follow-up, assessed at least 24 months.

  7. Consumption of medical resources

    Medical resource consumption is measured by the time of nurse reviews of remote monitoring data and alarm events.

    Time frame: From date of randomization until study completion, assessed at least 24 months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07798024
Responsible party
Wei Chen (Professor, First Affiliated Hospital, Sun Yat-Sen University) — Principal investigator
First posted
Sep 1, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 1, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion